The group's principal activity is to develop therapeutic products for the treatment of viral diseases and certain cancers. The group's proprietary drug technology utilizes specifically configured ribonucleic acid (MA) and is protected by more than 300 patents worldwide. The products of the group include Ampligen, Oragent Drugs. Ampligen is being developed clinically for three anti-viral indications: myalgic encephalomyelitis, human immunodeficiency virus associated disorders and chronic hepatitis B virus infection.
Executive Information
Name
Title
Email
William Carter
Chmn., CEO, Pres.
N/A
Anthony Bonelli
COO, Pres.
N/A
Robert Peterson
CFO
N/A
Carol Smith
VP - Manufacturing Quality Assurance, Process Development
N/A
Mei-June Liao
VP - Regulatory Affairs, Quality Control, Research, Development
